The Spanish regional governments put obstacles, today, to the combinations of the analogous drugs of the LPG-1 and the basal insulin in the treatment of type II diabetes.In fact, they limit them to patients with body mass index (BMI) greater than 30, that is, cases of important obesity.
And the reason is none other than its high price, since the scientific evidence that supports the results of these formulas is accumulated, all of them disseminated during the meeting diabetes and obesity organized by the homologous group of the SEMI in Malaga.
The president of this scientific society, Antonio Zapatero, has assured medical writing that administrations still do not authorize the use of LPG-1 combinations and basal insulin except in the case explained “despite the fact that in the United States they have been applied for the United Statesabout three years ”.
This last extreme has been confirmed and released, during the forum, by Professor Julio Rosxtock, of the University of Texas Southwestern Medical Center in Dallas (Texas, United States).
Indeed, as another internist, Miguel Camafort, of the Clinic Hospital in Barcelona, the American Medicine Agency (FDA), does have authorized its use, but the European does not yet have an explicit mention in this regard, nor the administrationSpanish.
International essay ‘Dual VII’
Zapatero, on the other hand, has cited the international essay ‘Dual VII’, in which the Fuenlabrada Hospital in Madrid participates, to demonstrate the revolutionary channel of the new pharmacological combinations for diabetes.
“The most liroglutida insulin formula resulted in a reduction in hypoglycemia - main complication of diabetes - 80 percent with equal or better metabolic control of the disease, in addition to favoring weight loss and even going down to halfThe dose of basal insulin for each patient, ”he has revealed.